Shitiz Sriwastava is a Neurology physician affiliated with University of Arkansas for Medical Sciences. OpenAlex indexes 127 publications with 2,054 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4301 W Markham St # 500
Little Rock, AR 722057101
Telephone
501-686-8000Provider last certified this registry record 19 Aug 2025.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year20251 payment
- TG Therapeutics, Inc.Program year20252 payments
- EMD Serono, Inc.Program year202440 payments$47,767openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
60.3%Gabapentinoids38.2%Gabapentin100%Part D≥37 patientsOther antiepileptics10.3%Topiramate100%Part D≥12 patients+ 2 more classes in this area
Cancer & immunology
21.1%CD20-directed Cytolytic Antibody15.2%Kesimpta Pen100%Part D<11 patientsPyrimidine Synthesis Inhibitor5.9%Teriflunomide100%Part D<11 patientsMusculoskeletal
12.3%Neuromuscular Blocker6.4%Botox100%Part D<11 patientsgamma-Aminobutyric Acid-ergic Agonist5.9%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnostic evolution in multiple sclerosis: A narrative review of the McDonald criteria from 2001 to 2024
Multiple Sclerosis and Related Disorders
2025 - Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis
Journal of Neuroimmunology
2024 - Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review
Journal of Central Nervous System Disease
2024 - Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort
Journal of the Neurological Sciences
2024 - Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review
Multiple Sclerosis and Related Disorders
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Webber, MD
University of Arkansas for Medical Sciences
Zhiqiang Qin
University of Arkansas for Medical Sciences
Taufiek Rajab
University of Arkansas for Medical Sciences
Everett Magann, MD
University of Arkansas for Medical Sciences
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”